LT3544B - Erection-inducing method and compositions - Google Patents

Erection-inducing method and compositions Download PDF

Info

Publication number
LT3544B
LT3544B LTIP1579A LTIP1579A LT3544B LT 3544 B LT3544 B LT 3544B LT IP1579 A LTIP1579 A LT IP1579A LT IP1579 A LTIP1579 A LT IP1579A LT 3544 B LT3544 B LT 3544B
Authority
LT
Lithuania
Prior art keywords
impotence
erection
composition
peptide
men
Prior art date
Application number
LTIP1579A
Other languages
English (en)
Lithuanian (lt)
Inventor
Thomas Gerstenberg
Jan Fahrenkrug
Bent Ottesen
Original Assignee
Senetek Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Senetek Plc filed Critical Senetek Plc
Publication of LTIP1579A publication Critical patent/LTIP1579A/xx
Publication of LT3544B publication Critical patent/LT3544B/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Load-Engaging Elements For Cranes (AREA)
  • Detergent Compositions (AREA)
  • Revetment (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
LTIP1579A 1989-09-18 1993-12-10 Erection-inducing method and compositions LT3544B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/408,754 US5236904A (en) 1989-09-18 1989-09-18 Erection-inducing methods and compositions

Publications (2)

Publication Number Publication Date
LTIP1579A LTIP1579A (en) 1995-06-26
LT3544B true LT3544B (en) 1995-11-27

Family

ID=23617626

Family Applications (1)

Application Number Title Priority Date Filing Date
LTIP1579A LT3544B (en) 1989-09-18 1993-12-10 Erection-inducing method and compositions

Country Status (24)

Country Link
US (1) US5236904A (ru)
EP (1) EP0493485B1 (ru)
JP (1) JP3149946B2 (ru)
KR (1) KR100230720B1 (ru)
AT (1) ATE210994T1 (ru)
AU (1) AU641184B2 (ru)
BR (1) BR9007662A (ru)
CA (1) CA2065270C (ru)
CZ (1) CZ280446B6 (ru)
DE (1) DE69033881T2 (ru)
DK (1) DK0493485T3 (ru)
ES (1) ES2170050T3 (ru)
FI (1) FI104231B1 (ru)
GE (1) GEP19981264B (ru)
HK (1) HK1011292A1 (ru)
HU (1) HU208088B (ru)
IL (1) IL95505A (ru)
LT (1) LT3544B (ru)
LV (1) LV10198B (ru)
NO (1) NO307498B1 (ru)
RO (1) RO116346B1 (ru)
RU (1) RU2098120C1 (ru)
SK (1) SK452490A3 (ru)
WO (1) WO1991004039A1 (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5447912A (en) * 1989-09-18 1995-09-05 Senetek, Plc Erection-inducing methods and compositions
US5242391A (en) * 1990-04-25 1993-09-07 Alza Corporation Urethral insert for treatment of erectile dysfunction
DE4117249C2 (de) * 1991-05-27 1998-05-14 Christian Dr Stief Linsidomin zur Behandlung erektiler Dysfunktionen
US5565466A (en) * 1993-08-13 1996-10-15 Zonagen, Inc. Methods for modulating the human sexual response
US5482039A (en) * 1994-03-25 1996-01-09 Vivus, Inc. Process for diagnosing erectile dysfunction, and related methods of treatment
US5583144A (en) * 1995-02-24 1996-12-10 Kral; John G. Methods for treating erectile impotence
US5731339A (en) * 1995-04-28 1998-03-24 Zonagen, Inc. Methods and formulations for modulating the human sexual response
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
US5994294A (en) * 1996-02-02 1999-11-30 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US5932538A (en) * 1996-02-02 1999-08-03 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US20030004170A1 (en) * 1997-05-19 2003-01-02 Zonagen, Inc. Combination therapy for modulating the human sexual response
US5947901A (en) * 1997-09-09 1999-09-07 Redano; Richard T. Method for hemodynamic stimulation and monitoring
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6011043A (en) * 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6482426B1 (en) 1998-09-17 2002-11-19 Zonagen, Inc. Compositions for the treatment of male erectile dysfunction
US6706682B2 (en) 1999-01-21 2004-03-16 The Trustees Of Columbia University In The City Of New York Uses of vascular endothelial growth factor in the treatment of erectile dysfunction
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6650943B1 (en) 2000-04-07 2003-11-18 Advanced Bionics Corporation Fully implantable neurostimulator for cavernous nerve stimulation as a therapy for erectile dysfunction and other sexual dysfunction
AU5984801A (en) * 2000-05-12 2001-11-20 Novalar Pharmaceuticals Inc Local anesthetic methods and kits
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US6885895B1 (en) * 2001-04-26 2005-04-26 Advanced Bionics Corporation Methods and systems for electrical and/or drug stimulation as a therapy for erectile dysfunction
AU2006222233B2 (en) * 2005-03-07 2011-05-12 Mondobiotech Ag Formulation for aviptadil
WO2007073486A2 (en) 2005-12-20 2007-06-28 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
US8841255B2 (en) 2005-12-20 2014-09-23 Duke University Therapeutic agents comprising fusions of vasoactive intestinal peptide and elastic peptides
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
EP2307038A4 (en) 2008-06-27 2013-03-27 Univ Duke THERAPEUTIC AGENTS COMPRISING ELASTINE-LIKE PEPTIDES
ES2870914T3 (es) * 2009-08-14 2021-10-28 Phasebio Pharmaceuticals Inc Péptidos intestinales vasoactivos modificados
US9913748B2 (en) 2009-10-30 2018-03-13 Avner Spector Method and apparatus for treatment of erectile dysfunction with extracorporeal shockwaves
CA2873553C (en) 2011-06-06 2020-01-28 Phasebio Pharmaceuticals, Inc. Use of modified vasoactive intestinal peptides in the treatment of hypertension
GB201221046D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of diagnosis
GB201221032D0 (en) * 2012-11-22 2013-01-09 Mens Health Ltd Method of treatment
ES2818824T3 (es) 2014-05-08 2021-04-14 Phasebio Pharmaceuticals Inc Composiciones que comprenden una proteína de fusión de VIP-ELP para su uso en el tratamiento de fibrosis quística
ES2822598T3 (es) 2015-02-09 2021-05-04 Phasebio Pharmaceuticals Inc Métodos y composiciones para tratar enfermedades y trastornos musculares
WO2019102310A1 (en) 2017-11-24 2019-05-31 Alaval (Pty) Ltd Vip formulation for management of inflammatory conditions

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3898329A (en) * 1971-09-17 1975-08-05 Sami I Said Vasoactive intestinal peptide, composition and method
DE3637157A1 (de) * 1985-11-01 1987-05-21 Byk Gulden Lomberg Chem Fab Arzneimittel zur behandlung erektiler dysfunktionen
JPS62246595A (ja) * 1986-04-17 1987-10-27 Eisai Co Ltd 気菅支拡張作用・降圧作用ペプタイド
US4939224A (en) * 1987-02-26 1990-07-03 The Salk Institute Biotechnology/Industrial Associates, Inc. Vasoactive intestinal peptide analogs
IL87055A (en) * 1988-07-08 1994-06-24 Illana Gozes Conjugates of vasoactive intestinal peptide (vip) and of fragments thereof and pharmaceutical compositions comprising them
SE463851B (sv) * 1988-09-02 1991-02-04 Amsu Ltd Komposition foer behandling av erektil dysfunktion via uretra

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AUTORIUS: "Pharmacologicar basis of therapeuthies"

Also Published As

Publication number Publication date
CZ452490A3 (en) 1995-09-13
EP0493485A1 (en) 1992-07-08
HU208088B (en) 1993-08-30
KR100230720B1 (en) 1999-11-15
DK0493485T3 (da) 2002-03-18
BR9007662A (pt) 1992-07-21
HUT60633A (en) 1992-10-28
AU6440490A (en) 1991-04-18
GEP19981264B (en) 1998-07-07
FI104231B (fi) 1999-12-15
RU2098120C1 (ru) 1997-12-10
AU641184B2 (en) 1993-09-16
FI921136A0 (fi) 1992-03-17
HK1011292A1 (en) 1999-07-09
JP3149946B2 (ja) 2001-03-26
SK279489B6 (sk) 1998-12-02
CA2065270C (en) 2003-01-14
DE69033881T2 (de) 2002-09-12
NO920915D0 (no) 1992-03-09
CA2065270A1 (en) 1991-03-19
LTIP1579A (en) 1995-06-26
CZ280446B6 (cs) 1996-01-17
NO307498B1 (no) 2000-04-17
ATE210994T1 (de) 2002-01-15
FI104231B1 (fi) 1999-12-15
WO1991004039A1 (en) 1991-04-04
RO116346B1 (ro) 2001-01-30
EP0493485B1 (en) 2001-12-19
IL95505A (en) 1997-03-18
DE69033881D1 (de) 2002-01-31
JPH05500513A (ja) 1993-02-04
HU9200874D0 (en) 1992-05-28
US5236904A (en) 1993-08-17
SK452490A3 (en) 1998-12-02
LV10198A (lv) 1994-10-20
FI921136A (fi) 1992-03-17
LV10198B (en) 1995-08-20
NO920915L (no) 1992-03-09
EP0493485A4 (en) 1993-08-18
ES2170050T3 (es) 2002-08-01

Similar Documents

Publication Publication Date Title
RU2098120C1 (ru) Фармацевтическая композиция для индуцирования эрекции у мужчин (варианты)
US5447912A (en) Erection-inducing methods and compositions
Zorgniotti et al. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence
Ishii et al. Intracavernous injection of prostaglandin E1 for the treatment of erectile impotence
Wespes et al. Venous impotence: pathophysiology, diagnosis and treatment
JP3310982B2 (ja) 男性の勃起機能不全を改善するための剤形及び方法
Gerstenberg et al. Intracavernous self-injection with vasoactive intestinal polypeptide and phentolamine in the management of erectile failure
Earle et al. Prostaglandin E1 therapy for impotence, comparison with papaverine
Nellans et al. Pharmacological erection: diagnosis and treatment applications in 69 patients
Derouet et al. Treatment of erectile dysfunction with external vacuum devices
US6187790B1 (en) Use of cilostazol for treatment of sexual dysfunction
Buvat et al. Venous incompetence: critical study of the organic basis of high maintenance flow rates during artificial erection test
Keogh et al. Treatment of impotence by intrapenile injections. A comparison of papaverine versus papaverine and phentolamine: a double-blind, crossover trial
CA1338555C (en) Agents for treatment of male impotence
Earle et al. The role of intracavernosal vasoactive agents to overcome impotence due to spinal cord injury
US6110489A (en) Use of quinolines and quinolones to treat male erectile dysfunction
JPH07506333A (ja) 勃起機能不全症治療用ピリジルグアニジン化合物
US6132753A (en) Treatment of sexual dysfunction in certain patient groups
Knispel et al. Influence of cause on choice of therapy in 174 patients with erectile dysfunction
US6303135B1 (en) Use of quinolines and quinolones to treat male erectile dysfunction
Iacono et al. Evaluation of penile deep arteries in psychogenic impotence by means of duplex ultrasonography
Mooradian et al. Biweekly intracavernous administration of papaverine for erectile dysfunction.
US20030105128A1 (en) Treatment of sexual dysfunction in certain patient groups
Jantos et al. Pharmacocavernosography in the evaluation of erectile failure
Mouritsen et al. The intracavernous injection of papaverine as a diagnostic procedure in patients with erectile dysfunction

Legal Events

Date Code Title Description
MM9A Lapsed patents

Effective date: 20101210